BioMed Research International

BioMed Research International / 2014 / Article
Special Issue

Pharmacological Application of Growth Factors: Basic and Clinical

View this Special Issue

Review Article | Open Access

Volume 2014 |Article ID 759473 |

Haitao Wang, Rikang Wang, Thilini Thrimawithana, Peter J. Little, Jiangping Xu, Zhong-Ping Feng, Wenhua Zheng, "The Nerve Growth Factor Signaling and Its Potential as Therapeutic Target for Glaucoma", BioMed Research International, vol. 2014, Article ID 759473, 10 pages, 2014.

The Nerve Growth Factor Signaling and Its Potential as Therapeutic Target for Glaucoma

Academic Editor: Jian Xiao
Received08 Mar 2014
Accepted12 Aug 2014
Published31 Aug 2014


Neuroprotective therapies which focus on factors leading to retinal ganglion cells (RGCs) degeneration have been drawing more and more attention. The beneficial effects of nerve growth factor (NGF) on the glaucoma have been recently suggested, but its effects on eye tissue are complex and controversial in various studies. Recent clinical trials of systemically and topically administrated NGF demonstrate that NGF is effective in treating several ocular diseases, including glaucoma. NGF has two receptors named high affinity NGF tyrosine kinase receptor TrkA and low affinity receptor p75NTR. Both receptors exist in cells in retina like RGC (expressing TrkA) and glia cells (expressing p75NTR). NGF functions by binding to TrkA or p75NTR alone or both together. The binding of NGF to TrkA alone in RGC promotes RGC’s survival and proliferation through activation of TrkA and several prosurvival pathways. In contrast, the binding of NGF to p75NTR leads to apoptosis although it also promotes survival in some cases. Binding of NGF to both TrkA and p75NTR at the same time leads to survival in which p75NTR functions as a TrkA helping receptor. This review discusses the current understanding of the NGF signaling in retina and the therapeutic implications in the treatment of glaucoma.

1. Introduction

Glaucoma is one of the leading causes of blindness worldwide. Glaucoma is characterized by retinal ganglion cell (RGC) degeneration and loss of visual field and it occurs with or without elevated intraocular pressure (IOP) [1]. Apoptosis or programmed cell death of RGCs and optic nerve degeneration may be the cause of blindness and it may occur in the state of elevated intraocular pressure; however, both RGC apoptosis and optic nerve atrophy, due to glaucoma, can occur independently of elevated IOP. Clinically, in addition to the lowering of IOP, one of the main targets of glaucoma therapy is to delay the apoptosis and promote the survival of RGC. Up to now, there is considerable evidence showing that attenuation of RGC degeneration is potentially an effective therapeutic strategy for treatment of glaucoma [2, 3]. Thus, therapeutic neuroprotection of RGCs aims to prevent or delay cell death and maintaining normal neuronal functions is an important alternative approach for the treatment of glaucoma.

Nerve growth factor (NGF) was discovered in 1948. It prevents neuronal apoptosis in primary cultured neurons and reduces neuronal degeneration in animal models of neurodegenerative diseases [4]. These results in animals have led to several clinical trials [5, 6]. In clinical studies, treatment with NGF was accompanied by beneficial effects on cognitive performance, but it also led to back pain [7]. Positive results from the use of NGF in the treatment of classical neurodegenerative diseases lead researchers to investigate the role of NGF of the treatment of glaucoma based on glaucoma being a neurodegenerative disease related to the damage of optic nerves. RGCs are special neurons which receive visual information from photoreceptors and transmit signals to several brain regions including the thalamus, hypothalamus, and mesencephalon and midbrain [8]. Although NGF treatment is effective in the treatment of glaucoma, in some studies, there are also some negative reports; one example is the proapoptotic effect of p75 neurotrophin receptor (p75NTR) in glia cells; binding of NGF to p75NTR is associated with retinal ganglion cell apoptosis [9]. Thus, an enhanced understanding of the molecular pathways and mechanisms is required to better appreciate and potentially exploit the therapeutic potential NGF and its signaling pathways for the treatment of glaucoma. In this review, we will examine the current understanding of the NGF signaling pathway and its potential as a therapeutic target for the treatment of glaucoma.

2. Nerve Growth Factor Receptors and Their Signaling Pathways

2.1. General Features of NGF and Its Similarity with Other Growth Factors

Growth factors are produced by our body and they have a very extensive role in the regulation of many cellular processes. The binding of growth factors to their receptors on the cell surface affects cellular survival, proliferation, and/or differentiation [10, 11]. For example, platelet-derived growth factor promotes the proliferation of glioblastoma cells through downregulation of miR-21 [12]; the breadth of actions of such an agent is apparent from the observation that it can also enhance glycosaminoglycan elongation on the proteoglycan biglycan and thereby plays a role in the initiation of atherosclerosis [13]. The pleiotropic growth factor, transforming growth factor-β, promotes wound healing, inhibits macrophage proliferation, and protects against nerve-injury-induced neuropathic pain [14].

NGF is another important polypeptide growth factor which functions to regulate the growth and survival of nerve cells; it was discovered by Rita Levi-Montalcini and Stanley Cohen in the 1950s [15]. NGF belongs to a family of factors also known as neurotrophins. Other members of the neurotrophin family include brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin 4/5 (NT-4/5); all of them are known for regulating brain development and functions [16]. NGF is formed by cleavage from Pro-NGF, which is the precursor protein form of NGF; however, the roles of Pro-NGF and NGF are not consistent; treatment with Pro-NGF in cervical ganglia neurons which express both of the NGF receptors p75NTR and tyrosine receptor kinase A (TrkA) leads to programmed cell death, whereas NGF treatment of these same neurons results in survival and axonal growth [17]. Free NGF displays multiple physiological actions, in the central nerve system. NGF possesses neurotrophic effects and is critical for the neurite outgrowth and survival and maintenance of neurons. Studies, in vitro and in vivo, have shown that NGF stimulates neurite outgrowth and axonal branching and extension [1820]. Most importantly, NGF has strong antiapoptotic effect and, with deprivation of NGF, neurons exhibit a series of morphological changes and eventually undergo apoptosis [21].

The clinical significance of NGF has been widely studied and it is recognized that NGF profoundly affects the development of both the young and the adult nervous systems [22]. In the central nervous system, NGF is a key neurotrophin and its dysregulation could be involved in various neuronal degeneration diseases such as Alzheimer’s disease and multiple sclerosis [23, 24]. Dysfunction of NGF may also be linked to mental or psychiatric disorders, such as schizophrenia, depression, and autism [2527]. Low levels of NGF in cerebrospinal fluid and a deficit of NGF signaling might provide the basis for the occurrence of these neurological diseases [27]. Besides its role in the CNS, there is evidence that NGF circulates throughout the body and plays roles in many organs [28]. For example, variability in NGF levels is associated with atherosclerosis and hence cardiovascular disease and also metabolic disorders such as diabetes and obesity [29, 30]. Specifically, NGF levels are decreased in atherosclerotic coronary vascular tissue and a decrease in plasma NGF could be detected in metabolic syndrome patients [31]. NGF deficits are the main cause of these diseases mentioned above, so, to some extent, supply of NGF to the target region may reverse the pathology of the diseases or alleviate the symptoms. However, the obstacle is the drug delivery technology and pharmacokinetic properties since the apparent need is to deliver NGF to the target region and specifically the target regions in order to reduce the adverse effects at other sites [32]. This obstacle will not occur if NGF is used topically, for example, in the application of NGF in the treatment of ocular disease, and we will illustrate these possibilities in the following sections.

NGF plays its role by binding to its receptors located in the surface of cells. TrkA is the high affinity catalytically active receptor for NGF. NGF binding to TrkA leads to the phosphorylation of TrkA and activation of its downstream targets, such as protein kinase B (Akt) or extracellular signal-regulated protein kinase 1/2 (ERK1/2), which eventually cause neural differentiation and prevention of apoptosis [33]. The other NGF receptor, p75NTR, is a low affinity receptor [34]. The precise role of p75NTR is complicated, and, depending upon the cellular context, it can promote cell survival, cell death, or growth inhibition; for example, treatment of normal eyes with an NGF mutant-selective p75NTR agonist causes progressive RGC death [35]; in contrast, p75NTR overexpression in breast tumor cells favors tumor survival and contributes to tumor resistance to drugs [36].

2.2. Signaling Pathway of NGF and Its Receptors

The affinity of NGF binding to p75NTR receptor is weaker than NGF binding to TrkA, but the cell type distribution of p75NTR is wider than that of TrkA; TrkA receptor is mainly expressed at neurons responsive to NGF: peripheral sensory neurons, sympathetic neurons, and basal forebrain cholinergic neurons [37], while the p75NTR receptor is more widely distributed. In addition to cells expressing the TrkA receptor, the p75NTR receptor could be detected in motor neurons, Schwann cells, and cerebellar Purkinje cells [38]. Signaling of NGF receptors is shown in Figure 1.

TrkA is the high affinity catalytic receptor for the NGF and it mediates the main effects of NGF, which include cell growth, the formation and regeneration of neurites, and avoidance of programmed cell death [39]. Binding of NGF to TrkA receptor facilitates receptor dimerization and autophosphorylation of its tyrosine residues. Activation (phosphorylation) of the TrkA receptor provides docking sites for effector molecules such as Shc which in turn induces the recruitment of a complex of Shc/Grb2, subsequent to which several downstream signaling cascades are initiated and propagated [40].

Phosphorylation of the TrkA receptor leads to the interaction of TrkA and phosphatidylinositiol-3 kinase (PI3K). PI3K is activated and recruited to the plasma membrane and leads to the production of phosphoinositide 3,4,5-trisphosphate and membrane translocation of the serine/threonine-protein kinases Akt and Akt activation [20]. Although there are other downstream targets of PI3K, the PI3K/Akt signaling pathway is particularly important for neuronal survival and the synthesis of many new cellular proteins. In one exemplar, pathway Akt phosphorylates the proapoptotic proteins, such as forkhead box-O transcription factors (FoxO) and B-cell lymphoma 2 family members, thereby inhibiting neuronal apoptosis [4143]. FoxO is a classic target of growth factor Trk receptor signaling [44, 45]; FoxO proteins are expressed in the detached retina [46]; therefore, phosphorylation of FoxO mediated by Akt may play a role in neurotrophins-mediated cell survival.

Another NGF-activated signaling pathway is the Ras-mediated activation of the mitogen-activated protein kinase (MAPK) pathway, which is initiated through recruitment and phosphorylation of Shc [47]. Ras is a membrane-associated G protein; the active Ras protein binds to and phosphorylates several proteins, including the protooncogene Raf. Raf, in turn, activates MAPK kinase (MEK) and phosphorylated MEK activates ERK1/2 [48]. Phosphorylated ERK1/2 may enter into nucleus and regulate the activity of many transcription factors including ETS domain-containing protein ELK1 [49]. ERK1/2 may also phosphorylate ribosomal S6 kinase (S6K), which leads to the phosphorylation of cyclic adenosine monophosphate response element binding protein, eventually affecting the regulation of the expression of NGF-inducible genes and, thus, contributing to neuronal differentiation or neurite outgrowth [50]. Besides the two pathways mentioned above, TrkA activation also leads to the survival and growth of neuronal cells through Phospholipase C gamma1 (PLCγ1) [51]. PLCγ1 supports activation of PKC signaling pathway and is thus involved in antimitogenic/mitogenic signaling.

The other receptor for NGF is p75NTR, but it is not a specific receptor for NGF as it also binds other neurotrophins, such as NT-3, NT-4/5, and BDNF [52]. The role of the p75NTR receptor is complicated. Binding of NGF with p75NTR with low affinity leads to apoptosis or cell survival in different cellular contexts [35, 36]. p75NTR can induce apoptosis both in vitro and in vivo. p75NTR activates Rac GTPase and activated c-jun N-terminal kinase (JNK), including an injury-specific isoform, JNK3 [53]. JNKs stimulate the expression of proapoptotic genes via the transactivation of specific transcription factors [54], so p75NTR can promote cell death. However, it also enhances cell survival; NGF treatment activates nuclear factor κB (NF-κB) through p75NTR and during this process, p75NTR-mediated NF-κB activation enhances the survival response of developing sensory neurons to nerve growth factor [55]. NF-κB is a nuclear transcription factor that regulates expression of a large number of genes that are critical for the regulation of cell survival. Thus, in summary, the p75NTR receptor activates apoptotic signaling through the JNK cascade or cell survival through NF-κB pathway.

NGF binds to both TrkA and p75NTR receptors when they coexpressed on the outer cell membrane, even though the affinity of TrkA with NGF is much higher. Studies in vitro have shown that neurons coexpressing p75NTR and TrkA respond to lower concentrations of NGF [56, 57], which means that p75NTR increases the responsiveness of TrkA to NGF. When the two receptors are coexpressed, the rate of association of NGF with TrkA increases compared to cells expressing TrkA alone [58]. The result infers that this interaction leads to the formation of binding sites with higher affinity for NGF than that of either receptor alone. Structural and mechanistic insights into NGF interactions with the TrkA and p75NTR receptors indicate that NGF could dimerize TrkA and p75NTR exists as a preformed oligomer that is not dissociated by NGF [59]. There is no evidence to show that TrkA and p75NTR interact directly, so they may interact indirectly through the convergence of downstream signaling pathways and/or share adaptor molecules, rather than through direct receptor-receptor interactions [59]. These data indicate that the final fate of cells coexpressing both TrkA and p75NTR is complicated with the functional response related to the abundance of each receptor and the different agonists.

3. Causes and Pathophysiology of Glaucoma

Glaucoma is a severe eye disease, which is usually associated with absolute or relative elevated fluid pressure within the eyes and gradually progressive visual field loss. One major risk factor for glaucoma is the raised IOP. However, other mechanisms must be involved in the pathology of glaucoma because glaucoma can develop in the absence of elevated IOP and, in the clinic, different individuals respond differently to the elevated pressure [60]. In some populations, patients may have high eye pressure for many years but this never leads to glaucoma. Molecular studies on the differential expression of human genes under conditions of elevated IOP revealed that MMP1, MMP10, CXCL2, and PDPN were general responders and were altered in almost all the patients with glaucoma whilst STATH, FBN2, TF, OGN, IL6, IGF1, CRYAB, and ELAM1 (marker for glaucoma) had very patient specific changes in expression [61].

Notwithstanding the above, among the several causes for glaucoma, elevated eye pressure is one of the most important and best recognized acceptable risk factors [62]. Besides elevated IOP, glaucoma is also thought to arise from a mutation in a single gene or a group of genes; for instance, it is well identified that MYOC mutations are a major cause of glaucoma [63, 64]. This notion is supported by the observation that people with a family history of glaucoma have higher risk of developing glaucoma. The relationship between glaucoma with gene mutations and phenotypes has been reviewed by Fan and Wiggs [65]. Other risk factors for glaucoma include severely restricted blood flow to the eye, prolonged use of steroids, and ethnic and gender factors. Figure 2 shows a model of insults and their involvement of glaucoma.

Optic nerve damage is a common optic neuropathy of glaucoma, which is characterized by loss of retinal ganglion cells [66]. Both the high pressure and relatively low pressure can develop nerve damage and lead to blindness if left untreated. The inconsistent relationship of glaucomatous optic neuropathy with ocular hypertension has provoked the generation of other hypotheses and investigations. Among these studies, excitatory neurotransmitter toxicity (such as excessive glutamate release), hypoperfusion, trophic factors, retinal ganglion cell/axon degeneration, and neuron loss have received attention [6770]. Neuroprotection is an effective strategy to attenuate RGC degeneration and facilitate the survival of optic nerves through blocking these risk factors associated with RGC loss in glaucoma. NGF plays an effect by preventing neuronal degeneration in animal models of neurodegenerative diseases [71, 72], so the application of NGF as a neuroprotective strategy for the medical treatment of glaucoma should be reasonable.

4. Interaction between NGF and Glaucoma

4.1. Glaucoma Alters the Expression of NGF and Its Receptors in Retinal Ganglion Cells and Visual Cortex

In normal conditions, primary cultured RGCs and transformed RGC-5 cells express various neurotrophins, such as brain-derived neurotrophic factor (BDNF), NGF, neurotrophin-3 (NT3), neurotrophin-4 (NT4), and also their relevant receptors, such as TrkA, p75NTR, or TrkB. RGC-5 cells also secrete NT3, BDNF, NGF, and NT4 into the cultured media [73]. In the visual system, the secretion of neurotrophins and the expression of their receptors maintain the morphological development; for example, neurotrophins and their receptors have been shown to exert various influences on guiding the morphological differentiation of neurons and controlling the functional plasticity of visual circuits; they may also participate in visual connectivity and the transmission of images into brain through optic nerve fibers [74].

While, in pathological conditions, such as glaucoma, the increased IOP will alter the level of NGF and NGF receptor expression, glaucoma significantly reduces the content of NGF in the cerebrospinal fluid (CSF) and lateral geniculate nucleus (LGN), but serum NGF protein levels may not be affected; this finding suggests that the NGF present in the CSF is most likely taken up by damaged retinal or brain neurons. Ongoing research shows that glaucoma increases the basal level of TrkA in the LGN and NGF administration further enhances this increase. However glaucoma had no effect on the expression of p75NTR at early stage, while NGF still enhanced the level of p75NTR; these results support the contention that glaucoma altered the basal level of NGF and NGF receptors in brain visual centers [75]. A relatively long term study showed that, after 7 days of ocular hypertension, the content of retinal NGF increased but it did so transiently. However, the TrkA receptor is upregulated and expression is sustained for a long period in RGCs [76]. After 28 days of ocular hypertension, the level of retinal BDNF increased significantly, but the hypertension had no effect on its receptor TrkB [76]. The TrkC receptor was also enhanced in Müller cells but not in retinal ganglion cells even though the level of NT-3 remained unchanged. Expression of retinal p75NTR increased late at day 28 [76]. These results are consistent with the observation in the neurodegeneration; transgenic mice of neurodegeneration showed a lower level of NGF and NGF deficits elicit a progressive neurodegeneration [77, 78]. In Alzheimer’s disease, NGF has been shown to be effective in preventing the onset of the central cholinergic deficit, so the role of NGF in RGC degeneration caused by glaucoma is certainly worthy of further investigation.

4.2. NGF Affects Synaptic Plasticity and Glaucoma-Associated Proteins in the Optic Nerve System

In the CNS, NGF possesses obvious effects on modulating neuronal inputs and thereby synaptic plasticity. NGF augmentation significantly enhanced cholinergic neuronal markers and facilitated induction of hippocampal long-term potentiation (LTP); moreover, blockade of endogenous NGF significantly reduced hippocampal LTP and impaired retention of spatial memory [79]. These findings provide evidence that NGF is essential for NGF hippocampal plasticity and learning. NGF also plays a role in neuronal plasticity in the optical system or visual cortex where monocular deprivation leads to decreased cell size and impairment of synaptic plasticity in visual cortex, while intraventricular administration of NGF prevents the cell shrinkage and demonstrated a substantial recovery of functional binocular connections [80]. This information indicates that neurotrophic factors may contribute to the regulation of experience-dependent modifications of synaptic connectivity in the visual cortex. Intracortical infusion of NGF into adult cat visual cortex can recreate ocular dominance plasticity, suggesting that NGF is also involved in the activity-dependent modification of synaptic connectivity in the adult brain [81]. GAP-43 and synaptophysin are two presynaptic elements in the visual cortex, which are highly related to synaptic plasticity. NGF treatment stimulates phosphorylation of GAP-43 and increases the level of synaptophysin immunoreactivity in adult visual cortex [82]. NGF treatment of the adult visual cortex modulates presynaptic terminals, possibly by inducing axonal sprouting and formation of new synapses, and these changes may play a role in the NGF-induced functional plasticity.

Optineurin (OPTN) and myocilin (MYOC) are two genes linked to glaucoma [83]. Rezaie et al. identified that OPTN may be an adult-onset glaucoma gene and speculated that wild-type optineurin played a neuroprotective role in the eye and optic nerve through the TNF-α pathway; accordingly, when OPTN was defective, it may lead to visual loss and optic neuropathy as typically seen in normal and high-pressure glaucoma [84]. This speculation was supported by the results that NGF treatment enhanced the endogenous levels of both OPTN and MYOC genes in PC12 cells [85]. These results demonstrate that NGF affects the expression of glaucoma-associated genes and their protein products. The data also indicate that NGF treatment may be an effective way to intervene in the process of glaucoma. However, the roles of OPTN and MYOC are complicated. OPTN overexpression induces an upregulation of the endogenous MYOC in both RGC and PC12 cells, while overexpressing MYOC does not affect the OPTN level. MYOC and OPTN contribute to the development of neurodegenerative glaucoma through different mechanisms. Overexpression of MYOC inhibits NGF-induced neurite outgrowth in both PC12 cells and RGC-5 cells, while transfection of optineurin leads to increased apoptosis [86]. The acute role of NGF and the glaucoma-associated proteins still needs further investigation and a specific gene knock-out mouse may serve this purpose. So far, a conditional knockout mouse line of OPTN has been generated and is available at the Wellcome Trust Sanger Institute [87]; Myoc-null mice have also been produced by Kim and coworkers [88]; these genetically altered mice are useful tools for understanding the physiological function of glaucoma-associated proteins; they can also be used to model the phenotype of glaucoma. In addition, these mouse lines provide a foundation for future efforts aimed at deciphering the role of NGF in the treatment of glaucoma.

4.3. Differential Effects Mediated by NGF Receptors in Glaucoma

As discussed above, the role of the receptors, TrkA and p75NTR, is not consistent in the CNS. It is widely accepted that sympathetic neuron survival is regulated positively by TrkA and negatively by p75NTR. The apoptotic effect of p75NTR signaling occurs only under suboptimal survival conditions, while TrkA-mediated responses occur when survival conditions are optimal [8991]. In fact, the survival response to NGF is mediated by competitive signaling between TrkA and p75NTR; as mentioned previously, p75NTR induces NF-κB and JNK activation, whereas TrkA mediates MAPK and Akt activation and when the two receptors are expressed together, TrkA blocks the p75NTR-mediated JNK activation, but NF-κB is unaffected [88, 90].

In the optical system, the two receptors may also function differently. In normal adult retinas, TrkA is expressed in RGCs, whereas P75 is expressed in glia. In contrast to results from in vitro studies, in vivo studies indicate that NGF binds to TrkA and p75NTR but fails to promote the survival of axotomized RGCs in the adult retina; however, TrkA agonists showed robust neuroprotective effects [92]. Pharmacological inhibition of p75NTR or in p75NTR knockout mice showed enhanced survival of axotomized RGCs. A combination of NGF or TrkA agonists with p75NTR antagonists further potentiated RGC neuroprotection in vivo [93]. Treatment with a mutant NGF that only activates TrkA affords significant neuroprotection. Supporting results were obtained for a biological response modifier that prevents endogenous NGF and pro-NGF from binding to p75NTR. Treatment of normal eyes with an NGF mutant-selective p75NTR agonist causes progressive RGC death, and, in injured eyes, it accelerates RGC death [35]. In a model of experimental glaucoma, the loss of RGC is accompanied by increased retinal p75 and Bax expression [9]. In summary, much data support the idea that NGF can be neuroprotective when acting on neuronal TrkA receptors on RGCs but engagement of p75NTR on glial cells antagonizes this effect. However, p75NTR cannot be viewed simply as a proapoptotic factor as in some situations; p75NTR may be a neuroprotective molecule [94] and p75NTR has beneficial effects on myelin formation and regeneration [95]. Thus, it is apparent that the role of p75NTR is complex and we need to unravel the precise role of p75NTR under different conditions and its related molecules during retinal development and degeneration.

5. Application of NGF in Retina Neurodegeneration and Glaucoma

NGF is a widely studied growth factor which possesses significant neuroprotective effects on neurons against various insults. In the central nervous system, NGF deficiency is involved in age-related neurodegenerative diseases; a deficit in the signaling and/or transport of NGF also leads to neurodegeneration [96]. Treatment with NGF can attenuate cholinergic deficit and improve cognitive behavior in animals. Clinical studies with chronic NGF administration in patients with Alzheimer’s disease normalized electroencephalograph patterns and improved performance in words recognition tests [97]. These researchers proposed that NGF or compounds that induce the expression of endogenous NGF may be useful in the treatment of Alzheimer’s disease or other neurodegenerative diseases. The application of NGF in the treatment of neurodegeneration prompts us to explore whether NGF will produce similar role in the treatment of optic nerve degeneration.

Sustained elevated IOP causes RGC degeneration and results in cell death. In animal models, glaucoma is induced by the injection of hypertonic saline into the episcleral vein of the eyes. A rat model of glaucoma showed that glaucoma led to progressive degeneration of RGCs, with the loss of nearly 40% of these cells after 7 weeks of treatment. The RGC loss is associated with the downregulation of NGF and NGF receptor expression in the retina and ocular treatment with NGF significantly reduced the deficit induced by glaucoma [98]. Another study showed that using NGF as an eye drop can attenuate the optic nerve damage that accompanies glaucoma; these investigators induced glaucoma in rats and measured the survival of RGCs with and without NGF eye drops administered four times daily for 7 weeks; it was found that significantly more RGCs survived in the treated group. In three patients with advanced glaucoma, treatment with topical NGF produced an improvement in visual acuity, contrast sensitivity, and electrophysiological functions [99]. What we should keep in mind is that most of the growth factors, including NGF, have low bioactive stability in the body owing to their short half-lives and slow diffusion, thus limiting its use as a neuroprotective drug [100]; ex vivo gene delivery or biologically stable small molecules that could bind and activate the TrkA signaling pathway are alternative strategies [101, 102]. From the angle of tissue engineering, two distinct strategies could be used for delivering growth factors: growth factors can be chemically bound into or onto the matrix; growth factors may infiltrate the material and make them available to cells. On the other hand, growth factors could also be physically encapsulated in the delivery system, and they can be released from synthetic extracellular matrix to target specific cell populations [103]; however, none has been evaluated for ocular applications. The most apparent advantage of NGF for the application in the clinic is its ability to penetrate to the retina when administrated topically. The application of NGF may open therapeutic perspectives for glaucoma and other neurodegenerative diseases.

6. Conclusions and Future Research

The ultimate goal of glaucoma research is to find new compounds that will not only normalize IOP but also arrest or even reverse apoptotic damage to the optic nerve and RGCs and slow the rate of progression of the disease. This review discussed current knowledge of glaucoma, with an emphasis on the NGF and NGF receptor(s) signaling pathways, and further explored the possibility of targeting the NGF signaling pathway as a strategy for the treatment of glaucoma. NGF offers the promise of actually restoring visual function through acting on the TrkA receptor; however, we should be cautious regarding the future of NGF-dependent treatments in the armamentarium of glaucoma therapy as most of the present studies were in animal models and none has reached clinical success. After more research and deeper mechanistic understanding a randomized, controlled glaucoma, clinical trials need to be performed to evaluate the therapeutic effect of NGF in the treatment of glaucoma and this also will involve an evaluation of the magnitude and occurrence rate of adverse effects. In the future, developments of novel pharmacological interventions for glaucoma may include the development of small molecules that are specific for TrkA receptors in the optical nerves. With protein chemistry entering into a new phase of “peptide design,” it is hoped that careful design of these small molecules may be able to limit biological activity to only the wanted effects and minimize the adverse effects. Other strategies such as chemical immobilization of NGF into or onto the matrix and physical encapsulation of NGF in the delivery system may also be promising in the future studies. Such novel ideas for trophic support are still developing and may provide future “smart drugs” for glaucoma.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


This research was financially supported by National Natural Science Foundation of China (no. 30670652; no. 30970935; and no. 31371088), the Guangdong Provincial Project of Science and Technology (nos. 2010A030100006 and 2011B050200005), and Director’s Fund of State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.


  1. M. V. Boland, A.-M. Ervin, D. S. Friedman et al., “Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. preventive services task force,” Annals of Internal Medicine, vol. 158, no. 4, pp. 271–279, 2013. View at: Publisher Site | Google Scholar
  2. L. Feng, Y. Zhao, M. Yoshida et al., “Sustained ocular hypertension induces dendritic degeneration of mouse retinal ganglion cells that depends on cell type and location,” Investigative Ophthalmology & Visual Science, vol. 54, no. 2, pp. 1106–1117, 2013. View at: Publisher Site | Google Scholar
  3. R. H. Foxton, A. Finkelstein, S. Vijay et al., “VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma,” The American Journal of Pathology, vol. 182, no. 4, pp. 1379–1390, 2013. View at: Publisher Site | Google Scholar
  4. M. V. Sofroniew, C. L. Howe, and W. C. Mobley, “Nerve growth factor signaling, neuroprotection, and neural repair,” Annual Review of Neuroscience, vol. 24, pp. 1217–1281, 2001. View at: Publisher Site | Google Scholar
  5. S. J. Allen, J. J. Watson, D. K. Shoemark, N. U. Barua, and N. K. Patel, “GDNF, NGF and BDNF as therapeutic options for neurodegeneration,” Pharmacology and Therapeutics, vol. 138, no. 2, pp. 155–175, 2013. View at: Publisher Site | Google Scholar
  6. L. U. Wahlberg, G. Lind, P. M. Almqvist et al., “Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery,” Journal of Neurosurgery, vol. 117, no. 2, pp. 340–347, 2012. View at: Publisher Site | Google Scholar
  7. J. M. Eriksdotter, A. Nordberg, K. Amberla et al., “Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease,” Dementia and Geriatric Cognitive Disorders, vol. 9, no. 5, pp. 246–257, 1998. View at: Publisher Site | Google Scholar
  8. L. A. Quina, W. Pak, J. Lanier et al., “Brn3a-expressing retinal ganglion cells project specifically to thalamocortical and collicular visual pathways,” The Journal of Neuroscience, vol. 25, no. 50, pp. 11595–11604, 2005. View at: Publisher Site | Google Scholar
  9. M. Coassin, A. Lambiase, V. Sposato, A. Micera, S. Bonini, and L. Aloe, “Retinal p75 and bax overexpression is associated with retinal ganglion cells apoptosis in a rat model of glaucoma,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 12, pp. 1743–1749, 2008. View at: Publisher Site | Google Scholar
  10. A. S. Felix, R. P. Edwards, R. A. Stone et al., “Associations between hepatocyte growth factor, c-Met, and basic fibroblast growth factor and survival in endometrial cancer patients,” The British Journal of Cancer, vol. 106, no. 12, pp. 2004–2009, 2012. View at: Publisher Site | Google Scholar
  11. B. P. Madakashira, D. A. Kobrinski, A. D. Hancher et al., “Frs2α enhances fibroblast growth factor-mediated survival and differentiation in lens development,” Development, vol. 139, no. 24, pp. 4601–4612, 2012. View at: Publisher Site | Google Scholar
  12. P. M. Costa, A. L. Cardoso, L. F. P. de almeida, J. N. Bruce, P. Canoll, and M. C. P. de lima, “PDGF-B-mediated downregulation of miR-21: new insights into PDGF signaling in glioblastoma,” Human Molecular Genetics, vol. 21, no. 23, Article ID dds358, pp. 5118–5130, 2012. View at: Publisher Site | Google Scholar
  13. R. Getachew, M. L. Ballinger, M. L. Burch et al., “PDGF β-receptor kinase activity and ERK1/2 mediate glycosaminoglycan elongation on biglycan and increases binding to LDL,” Endocrinology, vol. 151, no. 9, pp. 4356–4367, 2010. View at: Publisher Site | Google Scholar
  14. A. Lantero, M. Tramullas, A. Díaz, and M. A. Hurlé, “Transforming growth factor-β in normal nociceptive processing and pathological pain models,” Molecular Neurobiology, vol. 45, no. 1, pp. 76–86, 2012. View at: Publisher Site | Google Scholar
  15. W. M. Cowan, “Viktor Hamburger and Rita Levi-Montalcini: the path to the discovery of nerve growth factor,” Annual Review of Neuroscience, vol. 24, pp. 551–600, 2001. View at: Publisher Site | Google Scholar
  16. C. Lanave, A. M. Colangelo, C. Saccone, and L. Alberghina, “Molecular evolution of the neurotrophin family members and their Trk receptors,” Gene, vol. 394, no. 1-2, pp. 1–12, 2007. View at: Publisher Site | Google Scholar
  17. R. Lee, P. Kermani, K. K. Teng, and B. L. Hempstead, “Regulation of cell survival by secreted proneurotrophins,” Science, vol. 294, no. 5548, pp. 1945–1948, 2001. View at: Publisher Site | Google Scholar
  18. B. A. Tucker, M. Rahimtula, and K. M. Mearow, “Src and FAK are key early signalling intermediates required for neurite growth in NGF-responsive adult DRG neurons,” Cellular Signalling, vol. 20, no. 1, pp. 241–257, 2008. View at: Publisher Site | Google Scholar
  19. Z. Hu, M. Ulfendahl, and N. P. Olivius, “NGF stimulates extensive neurite outgrowth from implanted dorsal root ganglion neurons following transplantation into the adult rat inner ear,” Neurobiology of Disease, vol. 18, no. 1, pp. 184–192, 2005. View at: Publisher Site | Google Scholar
  20. L. Xu, S. Zhou, G.-Y. Feng et al., “Neural stem cells enhance nerve regeneration after sciatic nerve injury in rats,” Molecular Neurobiology, vol. 46, no. 2, pp. 265–274, 2012. View at: Publisher Site | Google Scholar
  21. D. J. Lomb, L. A. Desouza, J. L. Franklin, and R. S. Freeman, “Prolyl hydroxylase inhibitors depend on extracellular glucose and hypoxia-inducible factor (HIF)-2α to inhibit cell death caused by nerve growth factor (NGF) deprivation: evidence that HIF-2α has a role in NGF-promoted survival of sympathetic neurons,” Molecular Pharmacology, vol. 75, no. 5, pp. 1198–1209, 2009. View at: Publisher Site | Google Scholar
  22. M. H. Tuszynski and A. Blesch, “Nerve growth factor: from animal models of cholinergic neuronal degeneration to gene therapy in Alzheimer's disease,” Progress in Brain Research, vol. 146, pp. 441–449, 2004. View at: Google Scholar
  23. A. Cattaneo and P. Calissano, “Nerve growth factor and Alzheimer's disease: new facts for an old hypothesis.,” Molecular neurobiology, vol. 46, no. 3, pp. 588–604, 2012. View at: Publisher Site | Google Scholar
  24. K. Biernacki, J. P. Antel, M. Blain, S. Narayanan, D. L. Arnold, and A. Prat, “Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis,” Archives of Neurology, vol. 62, no. 4, pp. 563–568, 2005. View at: Publisher Site | Google Scholar
  25. J. E. McGeary, V. Gurel, V. S. Knopik, J. Spaulding, and J. McMichael, “Effects of nerve growth factor (NGF), fluoxetine, and amitriptyline on gene expression profiles in rat brain,” Neuropeptides, vol. 45, no. 5, pp. 317–322, 2011. View at: Publisher Site | Google Scholar
  26. K. B. Nelson, J. K. Grether, L. A. Croen et al., “Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation,” Annals of Neurology, vol. 49, no. 5, pp. 597–606, 2001. View at: Publisher Site | Google Scholar
  27. W. Zheng, H. Wang, Z. Zeng et al., “The possible role of the Akt signaling pathway in schizophrenia,” Brain Research, vol. 1470, pp. 145–158, 2012. View at: Publisher Site | Google Scholar
  28. R. Levi-Montalcini, “The nerve growth factor and the neuroscience chess board,” Progress in brain research, vol. 146, pp. 525–527, 2004. View at: Google Scholar
  29. G. N. Chaldakov, I. S. Stankulov, M. Fiore, P. I. Ghenev, and L. Aloe, “Nerve growth factor levels and mast cell distribution in human coronary atherosclerosis,” Atherosclerosis, vol. 159, no. 1, pp. 57–66, 2001. View at: Publisher Site | Google Scholar
  30. L. Manni, V. Nikolova, D. Vyagova, G. N. Chaldakov, and L. Aloe, “Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes,” International Journal of Cardiology, vol. 102, no. 1, pp. 169–171, 2005. View at: Publisher Site | Google Scholar
  31. H. T. Cheng, J. R. Dauch, J. M. Hayes, B. M. Yanik, and E. L. Feldman, “Nerve growth factor/p38 signaling increases intraepidermal nerve fiber densities in painful neuropathy of type 2 diabetes,” Neurobiology of Disease, vol. 45, no. 1, pp. 280–287, 2012. View at: Publisher Site | Google Scholar
  32. G. N. Chaldakov, M. Fiore, I. S. Stankulov et al., “Neurotrophin presence in human coronary atherosclerosis and metabolic syndrome: a role for NGF and BDNF in cardiovascular disease?” Progress in Brain Research, vol. 146, pp. 279–289, 2004. View at: Publisher Site | Google Scholar
  33. R. Romon, E. Adriaenssens, C. Lagadec, E. Germain, H. Hondermarck, and X. le Bourhis, “Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways,” Molecular Cancer, vol. 9, article 157, 2010. View at: Publisher Site | Google Scholar
  34. D. Deponti, R. Buono, G. Catanzaro et al., “The low-affinity receptor for neurotrophins p75 NTR plays a key role for satellite cell function in muscle repair acting via RhoA,” Molecular Biology of the Cell, vol. 20, no. 16, pp. 3620–3627, 2009. View at: Publisher Site | Google Scholar
  35. Y. Bai, P. Dergham, H. Nedev et al., “Chronic and acute models of retinal neurodegeneration TrkA activity are neuroprotective whereas p75NTR activity is neurotoxic through a paracrine mechanism,” The Journal of Biological Chemistry, vol. 285, no. 50, pp. 39392–39400, 2010. View at: Publisher Site | Google Scholar
  36. S. Verbeke, S. Meignan, C. Lagadec et al., “Overexpression of p75NTR increases survival of breast cancer cells through p21waf1,” Cellular Signalling, vol. 22, no. 12, pp. 1864–1873, 2010. View at: Publisher Site | Google Scholar
  37. K.-F. Lee, A. M. Davies, and R. Jaenisch, “p75-deficient embryonic dorsal root sensory and neonatal sympathetic neurons display a decreased sensitivity to NGF,” Development, vol. 120, no. 4, pp. 1027–1033, 1994. View at: Google Scholar
  38. M. Bothwell, “Tissue localization of nerve growth factor and nerve growth factor receptors,” Current Topics in Microbiology and Immunology, vol. 165, pp. 55–70, 1991. View at: Google Scholar
  39. G. Niewiadomska, A. Mietelska-Porowska, and M. Mazurkiewicz, “The cholinergic system, nerve growth factor and the cytoskeleton,” Behavioural Brain Research, vol. 221, no. 2, pp. 515–526, 2011. View at: Publisher Site | Google Scholar
  40. S. K. Mahata, M. Mahata, H. Wu, R. J. Parmer, and D. T. O'Connor, “Neurotrophin activation of catecholamine storage vesicle protein gene expression: signaling to chromogranin a biosynthesis,” Neuroscience, vol. 88, no. 2, pp. 405–424, 1999. View at: Publisher Site | Google Scholar
  41. W.-H. Zheng, S. Kar, and R. Quirion, “Insulin-like growth factor-1-induced phosphorylation of transcription factor FKHRL1 is mediated by phosphatidylinositol 3-kinase/Akt kinase and role of this pathway in insulin-like growth factor-1-induced survival of cultured hippocampal neurons,” Molecular Pharmacology, vol. 62, no. 2, pp. 225–233, 2002. View at: Publisher Site | Google Scholar
  42. Y.-P. Xia, R.-L. Dai, Y.-N. Li et al., “The protective effect of sonic hedgehog is mediated by the phosphoinositide [corrected] 3-kinase/AKT/Bcl-2 pathway in cultured rat astrocytes under oxidative stress,” Neuroscience, vol. 209, pp. 1–11, 2012. View at: Publisher Site | Google Scholar
  43. H. Wang, X. Zhou, J. Huang et al., “The role of Akt/FoxO3a in the protective effect of venlafaxine against corticosterone-induced cell death in PC12 cells,” Psychopharmacology, vol. 228, no. 1, pp. 129–141, 2013. View at: Publisher Site | Google Scholar
  44. W.-H. Zheng, S. Kar, and R. Quirion, “FKHRL1 and its homologs are new targets of nerve growth factor Trk receptor signaling,” Journal of Neurochemistry, vol. 80, no. 6, pp. 1049–1061, 2002. View at: Publisher Site | Google Scholar
  45. W.-H. Zheng and R. Quirion, “Glutamate acting on N-methyl-D-aspartate receptors attenuates insulin-like growth factor-1 receptor tyrosine phosphorylation and its survival signaling properties in rat hippocampal neurons,” The Journal of Biological Chemistry, vol. 284, no. 2, pp. 855–861, 2009. View at: Publisher Site | Google Scholar
  46. W. Huang, G. Li, J. Qiu, P. Gonzalez, and P. Challa, “Protective effects of resveratrol in experimental retinal detachment,” PLoS ONE, vol. 8, no. 9, Article ID e75735, 2013. View at: Google Scholar
  47. W. Chen, J. L. Martindale, N. J. Holbrook, and Y. Liu, “Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and Shc,” Molecular and Cellular Biology, vol. 18, no. 9, pp. 5178–5188, 1998. View at: Google Scholar
  48. Z. Wang, Y. Liu, M. Takahashi et al., “N terminus of ASPP2 binds to Ras and enhances Ras/Raf/MEK/ERK activation to promote oncogene-induced senescence,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 1, pp. 312–317, 2013. View at: Publisher Site | Google Scholar
  49. Y.-T. Oh, P. Yue, W. Zhou et al., “Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling,” The Journal of Biological Chemistry, vol. 287, no. 1, pp. 257–267, 2012. View at: Publisher Site | Google Scholar
  50. H.-C. Cheng, H.-M. Shih, and Y. Chern, “Essential role of cAMP-response element-binding protein activation by A2A adenosine receptors in rescuing the nerve growth factor-induced neurite outgrowth impaired by blockage of the MAPK cascade,” The Journal of Biological Chemistry, vol. 277, no. 37, pp. 33930–33942, 2002. View at: Publisher Site | Google Scholar
  51. C. Cabeza, A. Figueroa, O. M. Lazo et al., “Cholinergic abnormalities, endosomal alterations and up-regulation of nerve growth factor signaling in Niemann-Pick type C disease,” Molecular Neurodegeneration, vol. 7, article 11, 2012. View at: Publisher Site | Google Scholar
  52. H. S. Je, F. Yang, Y. Ji, G. Nagappan, B. L. Hempstead, and B. Lu, “Role of pro-brain-derived neurotrophic factor (proBDNF) to mature BDNF conversion in activity-dependent competition at developing neuromuscular synapses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 39, pp. 15924–15929, 2012. View at: Publisher Site | Google Scholar
  53. A. W. Harrington, J. Y. Kim, and S. O. Yoon, “Activation of Rac GTPase by p75 is necessary for c-jun N-terminal kinase-mediated apoptosis,” Journal of Neuroscience, vol. 22, no. 1, pp. 156–166, 2002. View at: Google Scholar
  54. J. Liu and A. Lin, “Role of JNK activation in apoptosis: a double-edged sword,” Cell Research, vol. 15, no. 1, pp. 36–42, 2005. View at: Publisher Site | Google Scholar
  55. M. Hamanoue, G. Middleton, S. Wyatt, E. Jaffray, R. T. Hay, and A. M. Davies, “p75-Mediated NF-κB activation enhances the survival response of developing sensory neurons to nerve growth factor,” Molecular and Cellular Neurosciences, vol. 14, no. 1, pp. 28–40, 1999. View at: Publisher Site | Google Scholar
  56. P. A. Barker and E. M. Shooter, “Disruption of NGF binding to the low affinity neurotrophin receptor p75LNTR reduces NGF binding to TrkA on PC12 cells,” Neuron, vol. 13, no. 1, pp. 203–215, 1994. View at: Publisher Site | Google Scholar
  57. P. A. Hantzopoulos, C. Suri, D. J. Glass, M. P. Goldfarb, and G. D. Yancopoulos, “The low affinity NGF receptor, p75, can collaborate with each of the Trks to potentiate functional responses to the neurotrophins,” Neuron, vol. 13, no. 1, pp. 187–201, 1994. View at: Publisher Site | Google Scholar
  58. D. Mahadeo, L. Kaplan, M. V. Chao, and B. L. Hempstead, “High affinity nerve growth factor binding displays a faster rate of association than p140trk binding. Implications for multi-subunit polypeptide receptors,” Journal of Biological Chemistry, vol. 269, no. 9, pp. 6884–6891, 1994. View at: Google Scholar
  59. T. Wehrman, X. He, B. Raab, A. Dukipatti, H. Blau, and K. C. Garcia, “Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors,” Neuron, vol. 53, no. 1, pp. 25–38, 2007. View at: Publisher Site | Google Scholar
  60. S. L. Mansberger, B. A. Hughes, M. O. Gordon et al., “Comparison of initial intraocular pressure response with topical β-adrenergic antagonists and prostaglandin analogues in African American and white individuals in the ocular hypertension treatment study,” Archives of Ophthalmology, vol. 125, no. 4, pp. 454–459, 2007. View at: Publisher Site | Google Scholar
  61. N. Comes and T. Borrás, “Individual molecular response to elevated intraocular pressure in perfused postmortem human eyes,” Physiological Genomics, vol. 38, no. 2, pp. 205–225, 2009. View at: Publisher Site | Google Scholar
  62. B. J. Frankfort, A. Kareem Khan, D. Y. Tse et al., “Elevated intraocular pressure causes inner retinal dysfunction before cell loss in a mouse model of experimental glaucoma,” Investigative Ophthalmology & Visual Science, vol. 54, no. 1, pp. 762–770, 2013. View at: Publisher Site | Google Scholar
  63. S.-P. Cai, P. Muhemaiti, Y. Yin et al., “A novel MYOC heterzygous mutation identified in a Chinese Uygur pedigree with primary open-angle glaucoma,” Molecular Vision, vol. 18, pp. 1944–1951, 2012. View at: Google Scholar
  64. V. Mendoza-Reinoso, T. S. Patil, M. L. Guevara-Fujita et al., “Novel and known MYOC exon 3 mutations in an admixed Peruvian primary open-angle glaucoma population,” Molecular Vision, vol. 18, pp. 2067–2075, 2012. View at: Google Scholar
  65. B. J. Fan and J. L. Wiggs, “Glaucoma: genes, phenotypes, and new directions for therapy,” The Journal of Clinical Investigation, vol. 120, no. 9, pp. 3064–3072, 2010. View at: Publisher Site | Google Scholar
  66. J. B. Jonas, A. Bergua, P. Schmitz-Valckenberg, K. I. Papastathopoulos, and W. M. Budde, “Ranking of optic disc variables for detection of glaucomatous optic nerve damage,” Investigative Ophthalmology and Visual Science, vol. 41, no. 7, pp. 1764–1773, 2000. View at: Google Scholar
  67. C. T. Fu and D. W. Sretavan, “Ectopic vesicular glutamate release at the optic nerve head and axon loss in mouse experimental glaucoma,” The Journal of Neuroscience, vol. 32, no. 45, pp. 15859–15876, 2012. View at: Publisher Site | Google Scholar
  68. B. Junglas, S. Kuespert, A. A. Seleem et al., “Connective tissue growth factor causes glaucoma by modifying the actin cytoskeleton of the trabecular meshwork,” The American Journal of Pathology, vol. 180, no. 6, pp. 2386–2403, 2012. View at: Publisher Site | Google Scholar
  69. J. T. Wang, Z. A. Medress, and B. A. Barres, “Axon degeneration: molecular mechanisms of a self-destruction pathway,” Journal of Cell Biology, vol. 196, no. 1, pp. 7–18, 2012. View at: Publisher Site | Google Scholar
  70. Y. Lei, N. Garrahan, B. Hermann et al., “Topography of neuron loss in the retinal ganglion cell layer in human glaucoma,” British Journal of Ophthalmology, vol. 93, no. 12, pp. 1676–1679, 2009. View at: Publisher Site | Google Scholar
  71. C. V. Borlongan, “Recent preclinical evidence advancing cell therapy for Alzheimer's disease,” Experimental Neurology, vol. 237, no. 1, pp. 142–146, 2012. View at: Publisher Site | Google Scholar
  72. L.-Y. Li, J.-T. Li, Q.-Y. Wu et al., “Transplantation of NGF-gene-modified bone marrow stromal cells into a rat model of Alzheimer' disease,” Journal of Molecular Neuroscience, vol. 34, no. 2, pp. 157–163, 2008. View at: Publisher Site | Google Scholar
  73. N. Agarwal, R. Agarwal, D. M. Kumar et al., “Comparison of expression profile of neurotrophins and their receptors in primary and transformed rat retinal ganglion cells,” Molecular Vision, vol. 13, pp. 1311–1318, 2007. View at: Google Scholar
  74. S. Cohen-Cory and B. Lom, “Neurotrophic regulation of retinal ganglion cell synaptic connectivity: from axons and dendrites to synapses,” International Journal of Developmental Biology, vol. 48, no. 8-9, pp. 947–956, 2004. View at: Publisher Site | Google Scholar
  75. V. Sposato, V. Parisi, L. Manni et al., “Glaucoma alters the expression of NGF and NGF receptors in visual cortex and geniculate nucleus of rats: effect of eye NGF application,” Vision Research, vol. 49, no. 1, pp. 54–63, 2009. View at: Publisher Site | Google Scholar
  76. M. Rudzinski, T.-P. Wong, and H. U. Saragovi, “Changes in retinal expression of neurotrophins and neurotrophin receptors induced by ocular hypertension,” Journal of Neurobiology, vol. 58, no. 3, pp. 341–354, 2004. View at: Publisher Site | Google Scholar
  77. S. Capsoni, C. Tiveron, D. Vignone, G. Amato, and A. Cattaneo, “Dissecting the involvement of tropomyosin-related kinase A and p75 neurotrophin receptor signaling in NGF deficit-induced neurodegeneration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 27, pp. 12299–12304, 2010. View at: Publisher Site | Google Scholar
  78. S. Capsoni, C. Tiveron, G. Amato, D. Vignone, and A. Cattaneo, “Peripheral neutralization of nerve growth factor induces immunosympathectomy and central neurodegeneration in transgenic mice,” Journal of Alzheimer's Disease, vol. 20, no. 2, pp. 527–546, 2010. View at: Publisher Site | Google Scholar
  79. J. M. Conner, K. M. Franks, A. K. Titterness et al., “NGF is essential for hippocampal plasticity and learning,” The Journal of Neuroscience, vol. 29, no. 35, pp. 10883–10889, 2009. View at: Publisher Site | Google Scholar
  80. G. Carmignoto, R. Canella, P. Candeo, M. C. Comelli, and L. Maffei, “Effects of nerve growth factor on neuronal plasticity of the kitten visual cortex,” The Journal of Physiology, vol. 464, pp. 343–360, 1993. View at: Google Scholar
  81. S. T. Lockhart, J. N. Mead, J. M. Pisano, J. D. Slonimsky, and S. J. Birren, “Nerve growth factor collaborates with myocyte-derived factors to promote development of presynaptic sites in cultured sympathetic neurons,” Journal of Neurobiology, vol. 42, no. 4, pp. 460–476, 2000. View at: Google Scholar
  82. Y. Liu, K. F. Meiri, M. S. Cynader, and Q. Gu, “Nerve growth factor induced modification of presynaptic elements in adult visual cortex in vivo,” Brain Research, vol. 732, no. 1-2, pp. 36–42, 1996. View at: Publisher Site | Google Scholar
  83. K. K. McDonald, K. Abramson, M. A. Beltran et al., “Myocilin and optineurin coding variants in Hispanics of Mexican descent with POAG,” Journal of Human Genetics, vol. 55, no. 10, pp. 697–700, 2010. View at: Publisher Site | Google Scholar
  84. T. Rezaie, A. Child, R. Hitchings et al., “Adult-onset primary open-angle glaucoma caused by mutations in optineurin,” Science, vol. 295, no. 5557, pp. 1077–1079, 2002. View at: Publisher Site | Google Scholar
  85. B.-C. Park, M. Tibudan, M. Samaraweera, X. Shen, and B. Y. J. T. Yue, “Interaction between two glaucoma genes, optineurin and myocilin,” Genes to Cells, vol. 12, no. 8, pp. 969–979, 2007. View at: Publisher Site | Google Scholar
  86. T. Koga, X. Shen, J.-S. Park et al., “Differential effects of myocilin and optineurin, two glaucoma genes, on neurite outgrowth,” The American Journal of Pathology, vol. 176, no. 1, pp. 343–352, 2010. View at: Publisher Site | Google Scholar
  87. W. C. Skarnes, B. Rosen, A. P. West et al., “A conditional knockout resource for the genome-wide study of mouse gene function,” Nature, vol. 474, no. 7351, pp. 337–342, 2011. View at: Publisher Site | Google Scholar
  88. B. S. Kim, O. V. Savinova, M. V. Reedy et al., “Targeted disruption of the myocilin gene (Myoc) suggests that human glaucoma-causing mutations are gain of function,” Molecular and Cellular Biology, vol. 21, no. 22, pp. 7707–7713, 2001. View at: Publisher Site | Google Scholar
  89. J. Kohn, R. S. Aloyz, J. G. Toma, M. Haak-Frendscho, and F. D. Miller, “Functionally antagonistic interactions between the TrkA and p75 neurotrophin receptors regulate sympathetic neuron growth and target innervation,” Journal of Neuroscience, vol. 19, no. 13, pp. 5393–5408, 1999. View at: Google Scholar
  90. S. O. Yoon, P. Casaccia-Bonnefil, B. Carter, and M. V. Chao, “Competitive signaling between TrkA and p75 nerve growth factor receptors determines cell survival,” The Journal of Neuroscience, vol. 18, no. 9, pp. 3273–3281, 1998. View at: Google Scholar
  91. S. X. Bamji, M. Majdan, C. D. Pozniak et al., “The p75 neurotrophin receptor mediates neuronal apoptosis and is essential for naturally occurring sympathetic neuron death,” The Journal of Cell Biology, vol. 140, no. 4, pp. 911–923, 1998. View at: Publisher Site | Google Scholar
  92. Z. Shi, E. Birman, and H. U. Saragovi, “Neurotrophic rationale in glaucoma: a TrkA agonist, but not NGF or a p75 antagonist, protects retinal ganglion cells in vivo,” Developmental Neurobiology, vol. 67, no. 7, pp. 884–894, 2007. View at: Publisher Site | Google Scholar
  93. F. Lebrun-Julien, B. Morquette, A. Douillette, H. U. Saragovi, and A. Di Polo, “Inhibition of p75NTR in glia potentiates TrkA-mediated survival of injured retinal ganglion cells,” Molecular and Cellular Neuroscience, vol. 40, no. 4, pp. 410–420, 2009. View at: Publisher Site | Google Scholar
  94. B. D. Carter and G. R. Lewint, “Neurotrophins live or let die: does p75(NTR) decide?” Neuron, vol. 18, no. 2, pp. 187–190, 1997. View at: Publisher Site | Google Scholar
  95. J. M. Cosgaya, J. R. Chan, and E. M. Shooter, “The neurotrophin receptor p75NTR as a positive modulator of myelination,” Science, vol. 298, no. 5596, pp. 1245–1248, 2002. View at: Publisher Site | Google Scholar
  96. S. Capsoni, G. Ugolini, A. Comparini, F. Ruberti, N. Berardi, and A. Cattaneo, “Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 12, pp. 6826–6831, 2000. View at: Publisher Site | Google Scholar
  97. L. Olson, “NGF and the treatment of Alzheimer's disease,” Experimental Neurology, vol. 124, no. 1, pp. 5–15, 1993. View at: Publisher Site | Google Scholar
  98. V. Colafrancesco, V. Parisi, V. Sposato et al., “Ocular application of nerve growth factor protects degenerating retinal ganglion cells in a rat model of glaucoma,” Journal of Glaucoma, vol. 20, no. 2, pp. 100–108, 2011. View at: Publisher Site | Google Scholar
  99. A. Lambiase, L. Aloe, M. Centofanti et al., “Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: implications for glaucoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 32, pp. 13469–13474, 2009. View at: Publisher Site | Google Scholar
  100. K. Akassoglou, “Nerve growth factor-independent neuronal survival: a role for NO donors,” Molecular Pharmacology, vol. 68, no. 4, pp. 952–955, 2005. View at: Publisher Site | Google Scholar
  101. M. H. Tuszynski, L. Thal, M. Pay et al., “A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease,” Nature Medicine, vol. 11, no. 5, pp. 551–555, 2005. View at: Publisher Site | Google Scholar
  102. S. M. Massa, Y. Xie, and F. M. Longo, “Alzheimer's therapeutics: neurotrophin domain small molecule mimetics,” Journal of Molecular Neuroscience, vol. 20, no. 3, pp. 323–326, 2003. View at: Publisher Site | Google Scholar
  103. K. Lee, E. A. Silva, and D. J. Mooney, “Growth factor delivery-based tissue engineering: general approaches and a review of recent developments,” Journal of the Royal Society Interface, vol. 8, no. 55, pp. 153–170, 2011. View at: Publisher Site | Google Scholar

Copyright © 2014 Haitao Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.